CTOs on the Move

Taro Pharmaceuticals (HQ)

www.tarousa.com

 
"Taro Pharmaceuticals U.S.A., Inc., and its divisions, subsidiaries and affiliates (collectively, ""Taro"") operate a variety of websites designed to provide you with services ranging from valuable health resources to corporate news and product information"
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.tarousa.com
  • 3 Skyline Dr Ste 120
    Hawthorne, NY USA 10532
  • Phone: 914.345.9001

Executives

Name Title Contact Details

Similar Companies

Servier Pharmaceuticals

Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients` lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes.

I Holland Americas

I Holland Americas is a Fort Myers, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix`s proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.

United Pharma

United Pharma is a Fullerton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amplyx Pharmaceuticals

Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The resulting, new therapeutic creates a more targeted molecule with the goal of improving treatment outcomes and improving compliance with treatment regimens. Our initial development areas are in oncology and infectious disease.